3.0
14. Jan. 2013
Mitarbeiter (anonym)
Ehemaliger Mitarbeiter, mehr als 3 Jahre
Brisbane, CA
Empfehlen
CEO-Befürwortung
Geschäftsprognose
Pros
In general, the people and benefits are very good. The product is approved for Europe, but not US...yet, and meets specific needs of those with Idiopathic Pulmonary Fibrosis (IPF). Currently, there is no other approved product or treatment to help these people.
Kontras
Information sharing and communications could be better with the departments that are affected. Too often, it seemed like there was scrambling to meet deadlines that did not take into account all the necessary work involved. Some of the perks that helped maintain employee morale have been cut back or eliminated.